ALPHALISA IL-4 (RH) KIT,100PTS

Formats:

• Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
• Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
• Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

• No-wash steps, no separation steps
• ELISA alternative technology
• Sensitive detection
• Broad sample compatibility
• Small sample volume
• Results in less than 3 hours
• Half the time of an ELISA assay

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Interleukin 4 (IL4), also known as B Cell Stimulatory Factor 1, is an anti-inflammatory glycoprotein. It is produced by a variety of cells including Th2, mast cells, and basophils. Via binding to type 1 IL4 receptor, IL4 acts on hematopoietic cells and promotes class switching to IgE. A high level of IL4 has been associated with an increased production of IgE and allergy. This cytokine suppresses IFN γ and IL 8 production. It inhibits the production of inflammatory cytokines (IL1, IL6, and TNFα). In vivo, injection of IL4 has been shown to protect against experimental arthritis and immune complex-induced lung inflammation in rats. It could potentially be used in the treatment of chronic inflammatory diseases. IL4 may also play a role in the pathogenesis of chronic lymphocytic leukemia.